FoxO1 inhibition alleviates type 2 diabetes-related diastolic dysfunction by increasing myocardial pyruvate dehydrogenase activity

The GLP-1R agonist liraglutide increases myocardial glucose oxidation rates via indirect mechanisms and mitigates experimental diabetic cardiomyopathy

(2020) Malak Almutairi et al.   CANADIAN JOURNAL OF CARDIOLOGY

Pimozide Alleviates Hyperglycemia in Diet-Induced Obesity by Inhibiting Skeletal Muscle Ketone Oxidation

(2020) Rami Al Batran et al.   Cell Metabolism

Basic Mechanisms of Diabetic Heart Disease

(2020) Rebecca H. Ritchie et al.   CIRCULATION RESEARCH

FOXO1 contributes to diabetic cardiomyopathy via inducing imbalanced oxidative metabolism in type 1 diabetes

(2020) Dan Yan et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Tissue-specific regulation of p53 by PKM2 is redox dependent and provides a therapeutic target for anthracycline-induced cardiotoxicity

(2019) Bruno Saleme et al.   Science Translational Medicine

CalR : A Web-Based Analysis Tool for Indirect Calorimetry Experiments

(2018) Amir I. Mina et al.   Cell Metabolism

Diabetic Cardiomyopathy

(2018) Guanghong Jia et al.   CIRCULATION RESEARCH

Lipotoxicity in obesity and diabetes-related cardiac dysfunction

(2016) Igor Zlobine et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS

Epidemiology of heart failure: the prevalence of heart failure and ventricular dysfunction in older adults over time. A systematic review

(2016) Evelien E.S. van Riet et al.   EUROPEAN JOURNAL OF HEART FAILURE

Increasing Pyruvate Dehydrogenase Flux as a Treatment for Diabetic Cardiomyopathy: A Combined13C Hyperpolarized Magnetic Resonance and Echocardiography Study

(2015) Lydia M. Le Page et al.   DIABETES

Trimetazidine Therapy Prevents Obesity-Induced Cardiomyopathy in Mice

(2014) John R. Ussher et al.   CANADIAN JOURNAL OF CARDIOLOGY

Agonist-Induced Hypertrophy and Diastolic Dysfunction Are Associated With Selective Reduction in Glucose Oxidation

(2012) Jun Mori et al.   Circulation-Heart Failure

Metabolic stress–induced activation of FoxO1 triggers diabetic cardiomyopathy in mice

(2012) Pavan K. Battiprolu et al.   JOURNAL OF CLINICAL INVESTIGATION

NIH Image to ImageJ: 25 years of image analysis

(2012) Caroline A Schneider et al.   NATURE METHODS

Chronic Inhibition of Pyruvate Dehydrogenase in Heart Triggers an Adaptive Metabolic Response

(2011) Kari T. Chambers et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Pyruvate dehydrogenase inhibition by the inflammatory cytokine TNFα contributes to the pathogenesis of pulmonary arterial hypertension

(2011) Gopinath Sutendra et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

Discovery of Novel Forkhead Box O1 Inhibitors for Treating Type 2 Diabetes: Improvement of Fasting Glycemia in Diabetic db/db Mice

(2010) T. Nagashima et al.   MOLECULAR PHARMACOLOGY

Avoidance of Transient Cardiomyopathy in Cardiomyocyte-Targeted Tamoxifen-Induced MerCreMer Gene Deletion Models

(2009) Norimichi Koitabashi et al.   CIRCULATION RESEARCH

Insulin-Stimulated Cardiac Glucose Oxidation Is Increased in High-Fat Diet-Induced Obese Mice Lacking Malonyl CoA Decarboxylase

(2009) J. R. Ussher et al.   DIABETES

Obesity and nonalcoholic fatty liver disease: Biochemical, metabolic, and clinical implications

(2009) Elisa Fabbrini et al.   HEPATOLOGY

Regulation of pyruvate dehydrogenase kinase isoform 4 (PDK4) gene expression by glucocorticoids and insulin

(2009) Sara Connaughton et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Metabolic (In)Flexibility of the Diabetic Heart

(2008) Terje S. Larsen et al.   CARDIOVASCULAR DRUGS AND THERAPY

Impact of Gender on the Myocardial Metabolic Response to Obesity

(2008) Linda R. Peterson et al.   JACC-Cardiovascular Imaging